Moderna (MRNA) closed at $218.01 on Oct 16, 2026, down 7.8% on the day. The stock is up 37.9% over the past month, up 266.5% over three months, up 639.3% year to date and up 686.5% over the past year. It trades 10.0% below its 52-week high of $242.29 and 878.5% above its 52-week low of $22.28. The close sits above its 50-day moving average ($154.93) and above its 200-day moving average ($77.39).
NextPick tracks MRNA in its Biotech basket alongside VRTX, REGN, BIIB, ALNY and BNTX. As of Oct 16, 2026, the basket's money-flow score is -8 (neutral), and the basket is down 3.4% over five sessions. Over the past month MRNA ranks 1st of 17 basket members by price change.
MRNA, which rose 177% in one day, is still short squeeze after revaluation
The first mRNA cancer vaccine successfully achieved phase III, growing its market value to $45 billion overnight, though detailed data has yet to be released
Aug 19, 2026
Yes — the Oct 16, 2026 close of $218.01 is 181.7% above the 200-day average of $77.39.
MRNA closed 10.0% below its 52-week high of $242.29.
NextPick groups MRNA with VRTX, REGN, BIIB, ALNY and BNTX in its Biotech basket.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
